Why Are Biofrontera Shares Rising Today?

Biofrontera Inc BFRI has provided an update on the patient recruitment for the Phase 3 study for superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (PDT) combined with BF-RhodoLED lamp in the U.S. 

  • To date, 70% of the planned 186 patients have been enrolled in the study. 
  • Patient recruitment for this study has been ongoing since 2018, with the completion of patient recruitment anticipated by the end of 2022.
  • “Due to a demanding study protocol mandated by the FDA, the recruitment process has been taking a considerable amount of time and was additionally slowed down by the Covid pandemic, but has recently picked up again,” said CEO Erica Monaco.
  • Patients will receive one cycle of two PDTs 1-2 weeks apart, which may be repeated after three months if required. 
  • The last assessment of the patients will take place three months after the last PDT cycle. 
  • After completing the trial, Biofrontera will follow patients for an additional 5-year period. 
  • Each patient will be treated with Ameluz-PDT or placebo-PDT. 
  • The primary study endpoint is the composite complete clinical and histological clearance of the main sBCC lesion selected at the beginning of the study. 
  • Price Action: BFRI shares are up 21.20% at $4.11 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!